Xenon Pharmaceuticals Inc XENE

Healthcare Biotechnology

Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).

NDAQ:XENE - Post by User

Xenon Pharmaceuticals Inc

Bullboard Posts

Next >>

Post by BioTechGuru3314on Jun 25, 2019 1:15am

113 Views

Post# 29858902

Excellent company and drug

Extremely solid scientific backing and upcoming milestones which are looking VERY positive based on their previous data. Could easily 2x or be sold at a great valuation to big Pharma

Bullboard Posts

Next >>

Critical raw materials pioneer drives Europe’s clean energy transition